| Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non–small-cell lung cancer M Fukuoka, S Yano, G Giaccone, T Tamura, K Nakagawa, JY Douillard, ... Journal of clinical oncology 41 (6), 1162-1171, 2023 | 3903 | 2023 |
| The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer P Goldstraw, K Chansky, J Crowley, R Rami-Porta, H Asamura, ... Journal of Thoracic Oncology 11 (1), 39-51, 2016 | 3526 | 2016 |
| Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2 RS Herbst, G Giaccone, JH Schiller, RB Natale, V Miller, C Manegold, ... Journal of Clinical Oncology 22, 785-794, 2004 | 2308 | 2004 |
| Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. G Giaccone, RS Herbst, C Manegold, GV Scagliotti, R Rosell, V Miller, ... Journal of Clinical Oncology 22, 777-784, 2004 | 2277 | 2004 |
| Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists … NI Lindeman, PT Cagle, MB Beasley, DA Chitale, S Dacic, G Giaccone, ... Journal of Thoracic Oncology 8 (7), 823-859, 2013 | 1870 | 2013 |
| Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs MG Kris, BE Johnson, LD Berry, DJ Kwiatkowski, AJ Iafrate, II Wistuba, ... Jama 311 (19), 1998-2006, 2014 | 1683 | 2014 |
| Targeting the dynamic HSP90 complex in cancer J Trepel, M Mollapour, G Giaccone, L Neckers Nature reviews cancer 10 (8), 537-549, 2010 | 1609 | 2010 |
| Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study F Cappuzzo, T Ciuleanu, L Stelmakh, S Cicenas, A Szczésna, E Juhász, ... The lancet oncology 11 (6), 521-529, 2010 | 1530 | 2010 |
| Cell death independent of caspases: a review LE Broker, FAE Kruyt, G Giaccone Clinical Cancer Research 11 (9), 3155-3162, 2005 | 1303 | 2005 |
| American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non–small-cell lung cancer CG Azzoli, S Baker Jr, S Temin, W Pao, T Aliff, J Brahmer, DH Johnson, ... Journal of clinical oncology 27 (36), 6251, 2009 | 955 | 2009 |
| Atezolizumab for first-line treatment of PD-L1–selected patients with NSCLC RS Herbst, G Giaccone, F de Marinis, N Reinmuth, A Vergnenegre, ... New England Journal of Medicine 383 (14), 1328-1339, 2020 | 950 | 2020 |
| Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non–small-cell lung cancer GV Scagliotti, R Fossati, V Torri, L Crino, G Giaccone, G Silvano, ... Journal of the National Cancer Institute 95 (19), 1453-1461, 2003 | 805 | 2003 |
| Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non–small-cell lung cancer JP Van Meerbeeck, GWPM Kramer, PEY Van Schil, C Legrand, EF Smit, ... Journal of the National Cancer Institute 99 (6), 442-450, 2007 | 757 | 2007 |
| Epidermal growth factor receptor mutations and gene amplification in non–small-cell lung cancer: Molecular analysis of the IDEAL/INTACT gefitinib trials DW Bell, TJ Lynch, SM Haserlat, PL Harris, RA Okimoto, BW Brannigan, ... Journal of Clinical Oncology 23 (31), 8081-8092, 2005 | 730 | 2005 |
| American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non … VL Keedy, S Temin, MR Somerfield, MB Beasley, DH Johnson, ... Journal of clinical oncology 29 (15), 2121-2127, 2011 | 728 | 2011 |
| Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for … JP van Meerbeeck, R Gaafar, C Manegold, RJ Van Klaveren, ... Journal of Clinical Oncology 23 (28), 6881-6889, 2005 | 699 | 2005 |
| A phase I study of the natural killer T-cell ligand α-galactosylceramide (KRN7000) in patients with solid tumors G Giaccone, CJA Punt, Y Ando, R Ruijter, N Nishi, M Peters, ... Clinical Cancer Research 8 (12), 3702-3709, 2002 | 663 | 2002 |
| Systemic therapy for stage IV non–small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update N Hanna, D Johnson, S Temin, S Baker Jr, J Brahmer, PM Ellis, ... Journal of Clinical Oncology, 2017 | 637 | 2017 |
| Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. D Curran, T Sahmoud, P Therasse, J van Meerbeeck, PE Postmus, ... Journal of Clinical Oncology 16 (1), 145-152, 1998 | 612 | 1998 |
| Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial MC Garassino, O Martelli, M Broggini, G Farina, S Veronese, E Rulli, ... The lancet oncology 14 (10), 981-988, 2013 | 573 | 2013 |
